Darzalex®

Active substance

Daratumumab

Holder

Janssen-Cilag NV

Status

Closed

Indication

Patients who have relapsed and refractory multiple myeloma (MM), who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD

Public documents

Approbation

Information for the patient

Informed consent

Last update

01/03/2017

Last updated on 13/02/2024